Skip to main content
Explore URMC
menu

Become a TIN Site Investigator

University of Rochester researchers can participate as site investigators in multi-site clinical trials initiated by others in the Trial Innovation Network (TIN) through the Expression of Interest (EOI) process.

What you get

Lead investigators from across the TIN can use the EOI process to connect with the 60+ CTSA Program hubs and recruit participating sites for their clinical trials. (To learn how to initiate an EOI to recruit sites for your own multi-site clinical trial, visit our TIN Proposal Consultation page.)

When the UR TIN Liaison team receives an EOI request from the TIN, the Liaison team will reach out to relevant departments to gauge researchers’ interested in being a site investigator for the trial described in the EOI. Interested researchers may be asked to review one or all of the EOI components listed below:

  • EHR-based cohort assessment of the site
  • Site PI identification
  • Protocol review/feasibility assessment by the interested site PI
  • Budget review/feasibility assessment by the interested site PI

You can express your interest to join the trial as a site investigator after reviewing the EOI documents.

Standard Due Dates

The TIN EOI generally asks for a response within three weeks from the date the email arrived to the UR TIN Liaison Team.

Confidentiality

All documents shared in the TIN EOI are kept confidential and only disclosed to the extent necessary to provide the EOI services. University of Rochester School of Medicine and Dentistry executed the TIN Umbrella Confidential Disclosure Agreement (CDA), which is effective until July 31, 2028. To review the Protocol of the multi-site trial, the UR TIN Liaison team will help you to complete the CDA process.

Publications by UR TIN site investigators

DOSE trial

"Mechanisms to expedite pediatric clinical trial site activation: The DOSE trial experience." Contemporary clinical trials. 2022 Dec 25; :107067. Epub 2022 Dec 25.

STRESS trial

"Methylprednisolone for Heart Surgery in Infants - A Randomized, Controlled Trial." The New England Journal of Medicine. 2022 Nov 6; Epub 2022 Nov 06.

ACTIVE-1 trial

"Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19." medRxiv: the preprint server for health sciences.. 2022 Sep 26; Epub 2022 Sep 26.

ACTIVE-1 trial

 "Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19." medRxiv: the preprint server for health sciences. 2022 Sep 26; Epub 2022 Sep 26.

CSSC trial

"Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial." Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2022 May 17; Epub 2022 May 17.

CSSC trial

"Early Outpatient Treatment for Covid-19 with Convalescent Plasma." The New England journal of medicine. 2022 Mar 30; Epub 2022 Mar 30.

3/29/2022

CSSC trial

"How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?" Transfusion. 2022 Mar 29; Epub 2022 Mar 29.